Current treatment approaches to leishmaniasis

Current Opinion in Infectious Diseases

Volumn 16, Issue 5, 2003, Pages 397-401

  Berman, Jonathan ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cutaneous leishmaniasis; Liposomal amphotericin B; Miltefosine treatment; Visceral leishmaniasis

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY; ANTIPROTOZOAL AGENT; FLUCONAZOLE; IMIQUIMOD; KETOCONAZOLE; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; RIFAMPICIN; STIBOGLUCONATE SODIUM; ZINC;

CARDIOTOXICITY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; ENDEMIC DISEASE; HUMAN; INDIA; LEISHMANIA MAJOR; LIVER TOXICITY; MUSCULOSKELETAL DISEASE; NONHUMAN; PANCREAS DISEASE; PILOT STUDY; REVIEW; SKIN LEISHMANIASIS; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS;

AMPHOTERICIN B; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; CLINICAL TRIALS; FLUCONAZOLE; HUMANS; LEISHMANIASIS; PAROMOMYCIN; PENTAMIDINE; PHOSPHORYLCHOLINE;

EID: 0142043920     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200310000-00005     Document Type: Review

References (28)

1. Sundar S, More DK, Singh MK, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000; 31:1104-1107.
2. Thakur CP, Kanyok TP, Pandey AK, et al. Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study. Trans R Soc Trop Med Hyg 2000; 94:432-433.
3. Thakur CP, Kanyok TP, Pandey AK, et al. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 2000; 94:429-431.
4. Das VN, Ranjan A, Sinha AN, et al. A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis. J Assoc Physicians India 2001; 49:609-613.
5. Sundar S, Sinha PR, Agrawal NK, et al. A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate. Am J Trop Med Hyg 1998; 59:139-143.
6. Veeken H, Ritmeijer K, Seaman J, Davidson R. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop Med Int Health 2000; 5:312-317.
7. Moore E, O'Flaherty D, Heuvelmans H, et al. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull World Health Organ 2001; 79:388-393.
8. Ritmeijer K, Veeken H, Melaku Y, et al. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans R Soc Trop Med Hyg 2001; 95:668-672.
9. Sundar S, Jha TK, Thakur CP, et al. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg 2002; 66:143-146. This paper documents the dose response of the Indian disease to low, medium and high doses of liposomal amphotericin B.
10. Sundar S, Agrawal G, Rai M, et al. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 2001; 323:419-422.
11. Sundar S, Gupta LB, Rastogi V, et al. Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis. Trans R Soc Trop Med Hyg 2000; 94:200-204.
12. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347:1739-1746. This paper describes the most significant advance in anti-leishmanial therapy in the past 10 years, i.e. the first effective oral agent for visceral leishmaniasis, at least in India.
13. Romero GAS, Guerra MF, Paes MG, Macedo VO. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am J Trop Med Hyg 2001; 65:456-465.
14. Machado P, Araujo C, da Silva AT, et al. Failure of early treatment of cutaneous leishmaniasis in preventing the development of an ulcer. Clin Infect Dis 2002; 34:e69-e73.
15. Palacios R, Osorio LE, Grajalew LF, Ochoa MT. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. Am J Trop Med Hyg 2001; 64:187-193.
16. Wortmann G, Miller RS, Oster C, et al. A randomized, double-blind study of • the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clin Infect Dis 2002; 35:261-267. This article suggests that, in certain regions of the New World, the classic treatment with antimonials for cutaneous disease is more effective than previously thought.
17. Arevalo I, Ward B, Miller R, et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 2001; 33:1847-1851.
18. Soto JM, Toledo JT, Gutierrez P, et al. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. Am J Trop Med Hyg 2002; 66:147-151.
19. Arana BA, Mendoza CE, Rizzo NR, Kroeger A. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg 2001; 65:466-470.
20. Soto J, Fuya P, Herrera R, Berman J. Topical paromomycin/MBCL plus parenteral meglumine in the treatment of American cutaneous leishmaniasis: a controlled study. Clin Infect Dis 1998; 26:56-58.
21. Soto J, Toledo J, Gutierrez P, et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 2001; 33:E57-E61.
22. Alrajhi AA, Ibrahim EA, De Vol EB, et al. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002; 346:891-895. This is the first randomized, controlled study to show that an oral agent is effective for one form of cutaneous leishmaniasis (that due to L. major).
23. Esfandiarpour I, Alavi A. Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Int J Dermatol 2002; 41:521-524.
24. Momeni AZ, Reiszadae MR, Aminjavaheri M. Treatment of cutaneous leishmaniasis with a combination of allopurinol and low-dose meglumine antimoniate. Int J Dermatol 2002; 41:441-443.
25. Kochar DK, Aseri S, Sharma BV, et al. The role of rifampicin in the management of cutaneous leishmaniasis. Q J Med 2000; 93:733-737.
26. Gurei MS, Tatli N, Ozbilge H, et al. Efficacy of cryotherapy and intralesional pentostam in treatment of cutaneous leishmaniasis. J Egypt Soc Parasitol 2000; 30:169-176.
27. Salmanpour R, Handiani F, Nouhpisheh MK. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis. J Dermatolog Treat 2001; 12:159-162.
28. Sharquie KE, Najim RA, Farjou IB, Al-Timimi DJ. Oral zinc sulphate in the treatment of acute cutaneous leishmaniasis. Clin Exp Dermatol 2001; 26:21-26.